Standard

Safety and efficacy of rivaroxaban in pediatric cerebral venous thrombosis (Einstein-Jr CVT). / EINSTEIN-Jr Cerebral Venous Thrombosis trial investigators.
в: Blood Advances, Том 4, № 24, 2020, стр. 6250-6258.

Результаты исследований: Вклад в журнал › Статья › Рецензирование

Harvard

EINSTEIN-Jr Cerebral Venous Thrombosis trial investigators 2020, 'Safety and efficacy of rivaroxaban in pediatric cerebral venous thrombosis (Einstein-Jr CVT)', Blood Advances, Том. 4, № 24, стр. 6250-6258. https://doi.org/10.1182/bloodadvances.2020003244

APA

EINSTEIN-Jr Cerebral Venous Thrombosis trial investigators (2020). Safety and efficacy of rivaroxaban in pediatric cerebral venous thrombosis (Einstein-Jr CVT). Blood Advances, 4(24), 6250-6258. https://doi.org/10.1182/bloodadvances.2020003244

Vancouver

EINSTEIN-Jr Cerebral Venous Thrombosis trial investigators. Safety and efficacy of rivaroxaban in pediatric cerebral venous thrombosis (Einstein-Jr CVT). Blood Advances. 2020;4(24):6250-6258. doi: 10.1182/bloodadvances.2020003244

Author

EINSTEIN-Jr Cerebral Venous Thrombosis trial investigators. / Safety and efficacy of rivaroxaban in pediatric cerebral venous thrombosis (Einstein-Jr CVT). в: Blood Advances. 2020 ; Том 4, № 24. стр. 6250-6258.

BibTeX

@article{552d50c236ea48f2b2aa0debdb0768ef,
title = "Safety and efficacy of rivaroxaban in pediatric cerebral venous thrombosis (Einstein-Jr CVT)",
keywords = "SINOVENOUS THROMBOSIS, ANTICOAGULANT TREATMENT, ORAL RIVAROXABAN, RISK-FACTORS, GUIDELINE, CHILDREN, DEFINITION, DIAGNOSIS, HEPARIN",
author = "{EINSTEIN-Jr Cerebral Venous Thrombosis trial investigators} and Philip Connor and {van Kammen}, {Mayte S{\'a}nchez} and Lensing, {Anthonie W.A.} and Elizabeth Chalmers and Kriszti{\'a}n K{\'a}llay and Kerry Hege and Paolo Simioni and Tina Biss and Fanny Bajolle and Damien Bonnet and Sebastian Grunt and Riten Kumar and Olga Lvova and Rukhmi Bhat and {van Damme}, An and Joseph Palumbo and Amparo Santamaria and Paola Saracco and Jeanette Payne and Susan Baird and Kamar Godder and Veerle Labarque and Christoph Male and Ida Martinelli and Soto, {Michelle Morales} and Jayashree Motwani and Sanjay Shah and Hooimeijer, {Helene L.} and Prins, {Martin H.} and Dagmar Kubitza and Smith, {William T.} and Berkowitz, {Scott D.} and Pap, {Akos F.} and Madhurima Majumder and Paul Monagle and Coutinho, {Jonathan M.}",
year = "2020",
doi = "10.1182/bloodadvances.2020003244",
language = "English",
volume = "4",
pages = "6250--6258",
journal = "Blood Advances",
issn = "2473-9537",
publisher = "American Society of Hematology",
number = "24",

}

RIS

TY - JOUR

T1 - Safety and efficacy of rivaroxaban in pediatric cerebral venous thrombosis (Einstein-Jr CVT)

AU - EINSTEIN-Jr Cerebral Venous Thrombosis trial investigators

AU - Connor, Philip

AU - van Kammen, Mayte Sánchez

AU - Lensing, Anthonie W.A.

AU - Chalmers, Elizabeth

AU - Kállay, Krisztián

AU - Hege, Kerry

AU - Simioni, Paolo

AU - Biss, Tina

AU - Bajolle, Fanny

AU - Bonnet, Damien

AU - Grunt, Sebastian

AU - Kumar, Riten

AU - Lvova, Olga

AU - Bhat, Rukhmi

AU - van Damme, An

AU - Palumbo, Joseph

AU - Santamaria, Amparo

AU - Saracco, Paola

AU - Payne, Jeanette

AU - Baird, Susan

AU - Godder, Kamar

AU - Labarque, Veerle

AU - Male, Christoph

AU - Martinelli, Ida

AU - Soto, Michelle Morales

AU - Motwani, Jayashree

AU - Shah, Sanjay

AU - Hooimeijer, Helene L.

AU - Prins, Martin H.

AU - Kubitza, Dagmar

AU - Smith, William T.

AU - Berkowitz, Scott D.

AU - Pap, Akos F.

AU - Majumder, Madhurima

AU - Monagle, Paul

AU - Coutinho, Jonathan M.

PY - 2020

Y1 - 2020

KW - SINOVENOUS THROMBOSIS

KW - ANTICOAGULANT TREATMENT

KW - ORAL RIVAROXABAN

KW - RISK-FACTORS

KW - GUIDELINE

KW - CHILDREN

KW - DEFINITION

KW - DIAGNOSIS

KW - HEPARIN

UR - http://www.scopus.com/inward/record.url?scp=85098051228&partnerID=8YFLogxK

UR - https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=tsmetrics&SrcApp=tsm_test&DestApp=WOS_CPL&DestLinkType=FullRecord&KeyUT=000602609500018

U2 - 10.1182/bloodadvances.2020003244

DO - 10.1182/bloodadvances.2020003244

M3 - Article

AN - SCOPUS:85098051228

VL - 4

SP - 6250

EP - 6258

JO - Blood Advances

JF - Blood Advances

SN - 2473-9537

IS - 24

ER -

ID: 20453790